Cargando…
OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program
OBJECTIVE: Chronic migraine (CM) is a prevalent and disabling neurological disorder. Phase III REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical program assessed efficacy and safety of onabotulinumtoxinA (BOTOX®) for prophylaxis of headaches in adults with CM. This secondary analys...
Autores principales: | Aurora, SK, Dodick, DW, Diener, H-C, DeGryse, RE, Turkel, CC, Lipton, RB, Silberstein, SD |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033567/ https://www.ncbi.nlm.nih.gov/pubmed/24107267 http://dx.doi.org/10.1111/ane.12171 |
Ejemplares similares
-
OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT
por: Aurora, SK, et al.
Publicado: (2013) -
The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program
por: Silberstein, S, et al.
Publicado: (2013) -
OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients without medication overuse
por: Diener, HC, et al.
Publicado: (2013) -
Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
por: Silberstein, Stephen D, et al.
Publicado: (2015) -
OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
por: Dodick, D, et al.
Publicado: (2013)